PCSK9 and cystic kidney disease: Despite PCSK9 inhibitors effectively lowering LDL-C, our findings suggest that targeting PCSK9 alone may not sufficiently mitigate cystic kidney disease progression, possibly due to its limited role in renal-specific pathways.